SCHEMBL16062179

SCHEMBL16062179

Cc1cc(Nc2nc(C(F)(F)F)ccc2[N+](=O)[O-])on1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 1/20 0.41
▸ GAA P10253 2/20 0.39
▸ EDNRA P25101 1/20 0.37
▸ ATF1 P18846 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ MAPK1 P28482 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ GLA P06280 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ CES2 O00748 1/20 0.34
▸ ABCB11 O95342 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ AR P10275 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17481368 0.86 CTSB (0.40) EDNRAMAPK1ALDH1A1SMN1; SMN2LMNA
SCHEMBL16061453 0.80 EDNRA (0.43) EDNRAATF1NFKB1ALDH1A1GLA
SCHEMBL17582873 0.78 AKR1B1 (0.50) GAAMAPK1ALDH1A1MAPT
SCHEMBL17475834 0.74 FGFR4 (0.44) FGFR4NFKB1MAPK1ALDH1A1SMN1; SMN2
SCHEMBL17586643 0.73 KMT2A (0.47) GAAMAPK1LMNACYP1A2CYP3A4
SCHEMBL13730151 0.72 GSK3B (0.56) FGFR4MAPK1ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL5745561 0.71 PGK1 (0.47) FGFR4GAAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL17077889 0.69 MEN1 (0.51) NFKB1MAPK1ALDH1A1GLASMN1; SMN2
SCHEMBL29531896 0.68 FGFR4 (0.48) FGFR4GAAMAPK1ALDH1A1CYP3A4
SCHEMBL20202988 0.68 PKM (0.48) EDNRAMAPK1ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 — — EP disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 — — EP disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 — — US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 — — US disclosed
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-10-23 — — US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 — — US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 — — US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 — — US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 — — US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 — — US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 — — US disclosed
EP-2970277-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Knopp Biosciences LLC (US) 2016-01-20 — — EP disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 — — WO disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KCNA7, KCNA2, KCNK17 FGFR4 3283/4885GAA 3437/4885EDNRA 2786/4885
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 FGFR4 3283/4885GAA 3437/4885EDNRA 2786/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 FGFR4 3254/4885GAA 3474/4885EDNRA 2816/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 FGFR4 3283/4885GAA 3437/4885EDNRA 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback